Respiratory Abnormalities Resulting from Midcervical Spinal Cord Injury and their Reversal by Serotonin 1A Agonists in Conscious Rats

Howard Choi,1,2,3 Wei-Lee Liao,1,2,3 Kimberly M. Newton,1,3 Renna C. Onorio,1,3 Allyson M. King,1,3 Federico C. Desilets,1,3 Eric J. Woodard,1 Marc E. Eichler,1 Walter R. Frontera,2 Sunil Sabharwal,2,3 and Yang D. Teng1,2,3

1Department of Neurosurgery, Harvard Medical School, Brigham and Women’s Hospital and Children’s Hospital Boston, Boston, Massachusetts 02115,
2Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Boston, Massachusetts 02114, and
3Spinal Cord Injury Research and Service, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts 02132

Respiratory dysfunction after cervical spinal cord injury (SCI) has not been examined experimentally using conscious animals, although clinical SCI most frequently occurs in midcervical segments. Here, we report a C5 hemicontusion SCI model in rats with abnormalities that emulate human post-SCI pathophysiology, including spontaneous recovery processes. Post-C5 SCI rats demonstrated deficits in minute ventilation (Ve) responses to a 7% CO2 challenge that correlated significantly with lesion severities (no injury or 12.5, 25, or 50 mm × 10 g weight drop; New York University impactor; p < 0.001) and ipsilateral motor neuron loss (p = 0.016). Importantly, C5 SCI resulted in at least 4 weeks of respiratory abnormalities that ultimately recovered afterward. Because serotonin is involved in respiration-related neuroplasticity, we investigated the impact of activating 5-HT1A receptors on post-C5 SCI respiratory dysfunction. Treatment with the 5-HT1A agonist 8-hydroxy-2-(di-n-propylmino)tetralin (8-OH DPAT) (250 μg/kg, i.p.) restored hypercapnic Ve at 2 and 4 weeks after injury (i.e., ~39.2% increase vs post-SCI baseline; p = 0.033). Improvements in hypercapnic Ve response after single administration of 8-OH DPAT were dose dependent and lasted for ~4 h (p ≤ 0.038 and p ≤ 0.024, respectively). Treatment with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.), replicated the results, whereas pretreatment with a 5-HT1A-specific antagonist, 4-ido-N-[2-[4-(methoxyphenyl)-1-piperazinyl][ethyl]-N-2-pyridinyl-benzamide (3 mg/kg, i.p.) given 20 min before 8-OH DPAT negated the effect of 8-OH DPAT. These results imply a potential clinical use of 5-HT1A agonists for post-SCI respiratory disorders.

Key words: spinal cord injury; cervical; hemicontusion; respiration; serotonin 1A; buspirone

Introduction
Respiratory disorders are the leading cause of morbidity and mortality after spinal cord injury (SCI), affecting approximately half of all patients with a neurological deficit after SCI (Winslow and Rozovsky, 2003). Respiratory impairments resulting from cervical SCI, the most common clinical case, frequently render survivors chronically or permanently ventilator dependent, a sequela that can dramatically compromise quality of life (Winslow and Rozovsky, 2003). However, respiratory abnormalities after cervical injuries have not been studied in conscious animal models, and there are no respiratory stimulants that can counteract respiratory disturbances induced or perpetuated by hypoxia, hypovolemia, or obstructive sleep apnea (Mendelsohn et al., 1991; Lalley et al., 1994; Sahibzada et al., 2000). Administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT), the prototypical 5-HT1A-specific agonist, restored respiratory frequency (f), tidal volume (Vt), and minute ventilation (Ve) to pre-SCI levels in T8 SCI rats (Teng et al., 2003). These data suggested that stimulation of surviving respiratory motoneurons via systemic 5-HT1A agonists might become a novel therapy to improve post-SCI respiration.
Agonists of 5-HT_{1A} receptors have yet to be tested in animal models that closely emulate pathophysiology derived from clinical pathology commonly seen in clinical SCI. Of note, respiratory recovery in our T8 SCI model occurred consistently by 7 d after injury (Teng et al., 1999, 2003). Moreover, clinical SCI affects lower thoracic levels far less frequently than midcervical segments. The National Spinal Cord Injury Database (1993–1998) recorded that 47% of SCIs in the cohort were C4–C7 cases, with C5 carrying the greatest frequency (Go et al., 1995). We therefore hypothesized that a C5 hemicontusion model would adequately emulate the pathophysiology of clinical post-SCI respiratory dysfunction while offering practical surgical procedures, postinjury animal care, and survival rates appropriate for laboratory operations. We tested our hypothesis by using a well-established whole-body plethysmography (WB) system (Teng et al., 1999, 2003; Gray et al., 2001) and examined the therapeutic effects of 5-HT_{1A} agonists in conscious post-SCI rats.

Materials and Methods

Spinal cord hemicontusion injury. A 3.0 mm left-sided hemilaminectomy encompassing the caudal end of vertebral level C4 and the rostral end of vertebral level C5 was produced in female Sprague Dawley rats (236–298 g; Charles River Laboratories, Wilmington, MA) after anesthesia with intraperitoneal ketamine (75 mg/kg) and xylazine (10 mg/kg). We used the New York University (NYU) impactor, a standardized device for delivery of contusive SCI in rats (Gruter, 1992), to produce an incomplete hemicontusion injury at the C5 spinal cord level from a height of 12.5 mm (mild SCI; n = 12), 25 mm (moderate SCI; n = 13), or 50 mm (severe SCI; n = 16). Additional animals were given laminectomies only without SCI (n = 10) or no surgery and anesthesia at all (n = 9). We provided postoperative care as described previously (Teng et al., 1999, 2004).

Monitoring of respiratory parameters by plethysmography. Before baseline preoperative respiratory recordings, rats initially completed plethysmograph chamber acclimation training as described previously (Teng et al., 1999, 2003). In addition, a 20 min acclimation phase in the chamber preceded all initial respiratory data acquisition sessions for each rat. After acclimation, rats remained quietly in the chamber, allowing for the acquisition of data without physical signs of stress (e.g., defecation, urination). Respiratory data were measured noninvasively in unanesthetized, conscious, unrestrained, spontaneously breathing rats using a bias flow-ventilated WBP designed for rodents (Ply3213; Buxco Electronics, Wilmington, NC) (Gray et al., 2001). We used the Epstein barometric method to derive lung ventilation parameters from pressure fluctuations within chambers of fixed volume (Epstein et al., 1980). Pressure changes in the chamber were captured by a differential pressure transducer, amplified, and integrated by a software program (Biosystem XA 2.7.9; Buxco Electronics, Wilmington, NC) into volumes. A negative bias flow regulator, set to 1.5 L/min, ensured that fresh room air or alternatively concentrated CO_{2} gas was steadily supplied into the chambers and that CO_{2} from breaths expired from the animal did not accumulate. Hypercapnic gas mixtures contained either 7% CO_{2}, 90% O_{2}, and N_{2} balance or 5% CO_{2}, 90% O_{2}, and N_{2} balance. Hyperoxic (i.e., 90% O_{2}) gas was used to ensure that the brief respiratory drive surges were initiated by hypercarbia in our long-term studies (i.e., not from hypoxia that also affects the respiratory system) (Feldman et al., 2003). Respiratory parameters from the current study were all within ranges similar to those our laboratory reported previously in which 60% O_{2} was used (Teng et al., 1999, 2003). Periods when subjects were moving around in the plethysmograph chamber, sniffing, grooming, or otherwise not in a mode of quiet conscious breathing were marked by trained observers during data collection and were excluded from analysis (Teng et al., 1999, 2003; Gray et al., 2001; Stephenson and Gucciardi, 2002).

Drug administration. The 5-HT_{1A}-specific agonists 8-OH DPAT (Tocris Cookson, Ellisville, MO) and buspirone (Sigma, St. Louis, MO) were dissolved in 0.9% saline (adjusted to pH 7.4) and administered intraperitoneally in 0.5 ml of final injection volume per rat at doses of 125 or 250 μg/kg for 8-OH DPAT and 1.5 mg/kg for buspirone (Teng et al., 2003). The 5-HT_{1A} receptor-specific antagonist 4-ido-β-N-[4-methoxy-phenyl]-1-piperazinyl[ethyl]-N-2-pyridinyl-benzamide (p-MPPi) (Sigma, St. Louis, MO) was dissolved in 0.9% saline and given intraperitoneally at a dose of 3 mg/kg, pH 7.4 (final volume, 0.5 ml), before 8-OH DPAT administration (Teng et al., 2003).

Neurobehavioral studies. The forelimb functional test was done by using a modified Tarlov scale ranging from 0 (no movement) to 5 (normal, weight-bearing forelimb use) as described previously (Gale et al., 1985). To measure hindlimb function, we modified the Basso–Beattie–Bresnan (BBB) scoring protocol (the BBB scale ranges from 0 to 21, where 0 indicates total hindlimb paralysis and 21 indicates normal performance) (Basso et al., 1995) by referencing hindlimb movements on the injured side only with those of the forelimb on both the uninjured and injured sides to obtain scores of coordination resulting from dysfunction in the forepaw ipsilateral to the hemicontusion SCI. Because forelimb movement of the injured side alone was not precise enough to evaluate stepping, the intact side forelimb was used as a reference to best judge whether the affected hindlimb moved in combination with the ipsilateral forelimb (i.e., coordination; rats move ipsilateral forelimb and hindlimb simultaneously). Neurobehavioral scores for both the hemicontused and contralateral sides were recorded by two evaluators blinded to the injury doses of the experimental groups.

Histopathology. Rats for histopathological analysis were terminated at 4 weeks after SCI (n = 4 per group; i.e., mild, moderate, severe, or no hemicontusion injury) using intracardiac perfusion with 0.1 M phosphate buffer and 4% paraformaldehyde as described previously (Teng et al., 1999, 2003). Spinal cord histopathology using cresyl violet and solvent blue/hematoxylin and eosin stains were performed as described previously (Teng et al., 2004) to evaluate the dimensions and anatomical profiles of the lesion volume and to evaluate postcontusion motoneuronal loss (Noble and Wrathall, 1989; Teng et al., 1998). All experiments were conducted in strict compliance with the Laboratory Animal Welfare Act and the National Institutes of Health Guide for the Care and Use of Laboratory Animals after approval by the Animal Care and Use Committee of the Veterans Affairs Boston Healthcare System.

Experimental protocol. A total of 60 animals were used for this study. After 1 week of plethysmograph chamber acclimation training (Teng et al., 1999), preoperative baseline respiratory recording was performed for each rat in room air and 7% CO_{2}. SCI surgery for rats in the surgical groups was performed 24 h after baseline respiratory recording. Postoperative respiratory and neurobehavioral studies were performed at 1 d after SCI and then at 1, 2, 3, 4, and 6 weeks after SCI. At each WB session, respiratory parameters, including f, Vt, and Ve were collected for 5 min during room air ventilation. Each animal was then exposed to a gas mixture containing 7% CO_{2} for 7 min, and the same parameters were recorded. At the 2 week post-SCI period, we performed a separate study for all rats using 5% CO_{2} to confirm a respiratory dose–response to hypercapnia (i.e., to compare respiratory parameters under 0.03% (room air), 5%, and 7% CO_{2}). As described previously, only the last 2 min of data during either 5 or 7% hypercapnic challenge was used for analysis (Teng et al., 1999).

At 5 d after SCI, four randomly selected rats with severe hemicontusion SCI underwent a washout (i.e., a transformed dose–response) study of the respiratory effect of 8-OH DPAT (250 μg/kg, i.p.). Respiratory parameters in room air (for 5 min) and under 7% CO_{2} (7 min, with the last 2 min used for data analysis) were recorded 15 min after an intraperitoneal 8-OH DPAT injection, with the 12 min (5 plus 7 min) recording period repeated at the end of every consecutive hour for up to 5 h as described previously (Teng et al., 2003). Studies to evaluate the effects of 8-OH DPAT (250 μg/kg) across injury dose groups were performed at 2 and 4 weeks after SCI in subgroups of rats randomly sampled from each uninjured and hemicontused group (mild, n = 9; moderate, n = 9; severe, n = 12; uninjured controls, n = 13). Rats were allowed to rest at least 60 min in room air before being injected intraperitoneally with 8-OH DPAT (250 μg/kg). After a 15 min postinjection period, room air respiratory data were recorded for 5 min. Immediately after room air recording, each rat was then exposed to 7% CO_{2} for 7 min, and the last 2 min were used for data analysis.
Twelve rats in the severely injured group underwent additional testing with buspirone (1.5 mg/kg), p-MPPI (3 mg/kg), and a lower dose of 8-OH DPAT (125 µg/kg) separately. Because of the large number of tests performed at the 2 week post-SCI period and the lengthy waiting periods necessary to washout 8-OH DPAT, these tests were randomly divided over a 3 period that corresponded to days 13–15 after SCI. We delivered p-MPPI 20 min before 8-OH DPAT injection and recorded 5 min of room air respiratory data 5 min after the p-MPPI injection. Fifteen minutes after the 8-OH DPAT injection, respiratory parameters were recorded in room air for 5 min, followed by 7% CO2 for 7 min. Respiratory parameters were recorded 15 min after buspirone (1.5 mg/kg, i.p.) injection.

Statistics. Respiratory study data for the overall C5 hemicontusion model were analyzed by a generalized linear model (GLM) resulting from dissimilarities in the number of observations per subject (i.e., some rats were terminated at 4 weeks for histopathological study), constraining the use of standard ANOVA techniques (Kleinbaum et al., 1998). Post hoc linear regression was performed when general analysis showed a significant difference. The dependent variables were f, Vt, and Ve, whereas injury dose, body weight, and CO2 level were tested as predictors. Non-longitudinal multiple linear regression was used to examine short-term changes in injury dose, body weight, and CO2 level were tested as predictors. Non-longitudinal multiple linear regression was used to examine short-term changes in f during the acute post-SCI period. To examine the effects of the pharmacological agents, respiratory parameters were compared using repeated-measures ANOVA, with post hoc Tukey’s test (Teng et al., 2003). Correlations between Ve at the time the animals were killed and lesion size or motoneuronal counts were examined using Pearson correlation. Correlations between injury dose and lesion size or motoneuronal counts were examined using Spearman correlation. Statistics were performed using the STATA 8.2 statistical package (StataCorp, College Station, TX). We considered differences in data to be significant when p < 0.05. All interventions and primary data collection were performed in a blinded manner.

Results
C5 hemicontusion SCI produces lesion dose-dependent respiratory deficits

Clinical studies have revealed that deficits in post-SCI respiratory parameters correlate with injury severity (Linn et al., 2001). We therefore subjected rats to varying grades of contusive SCI at the C5 level, delegated as mild (10 g × 12.5 mm; n = 12), moderate (10 g × 25 mm; n = 13), or severe (10 g × 50 mm, n = 16) injury using an NYU impactor (Gruner, 1992). Because midline cervical SCI in rats dramatically impairs respiration and food procurement to cause very poor postoperative survival, we administered a left-sided hemicontusion injury. In anticipation of potentially greater morbidity and mortality in groups receiving more severe injury doses, we assigned higher numbers of subjects to these groups. Only one rat each in the moderate and severely injured groups died postoperatively, however, with subsequent removal of their data from the study. Control rats received C5 left hemilaminectomy only without SCI (n = 10) or no surgery (n = 9).

To avoid the potential artifacts stemming from physical restraints (Teng et al., 1999, 2003), anesthesia (Teng and Wrathall, 1996), or instrumentation (Teng and Wrathall, 1996), we measured respiratory parameters noninvasively in conscious, spontaneously breathing rats using WBP after sufficient acclimation (Fig. 1) (Teng et al., 1999, 2003). Respiratory parameters (i.e., f, Vt, and Ve) for controls and for rats before surgery in room air and under hypercapnic conditions (data not shown) were consistent with the literature (Lai et al., 1978; Teng et al., 1999, 2003). No significant differences in body weight or respiratory function recordings were detected between the group that received C5 hemilaminectomy only and the nonoperative group at any time point (data not shown), and their data were therefore combined to form a single control group (n = 19; Teng et al., 1998). Body weights in rats with hemicontusion injury decreased during the initial post-SCI period in correlation with injury dose (e.g., |r| = 0.616; p < 0.001 at 7 d; Spearman correlation) (Fig. 2A). By week 6 after SCI, there was only a weak correlation between body weight and injury dose (|r| = 0.255; p = 0.024; Spearman correlation); rats given mild or moderate injury recovered their body weights to levels comparable with controls.

Primary data analysis using a GLM revealed that lesion dose (i.e., uninjured controls or mild, moderate, or severe hemicontusion injury) had a significant effect on Vt and Ve (p < 0.001), but not f (p = 0.116), over the 6 week post-SCI course (Table 1). Importantly, post hoc multiple linear regression analyses showed that groups receiving hemicontusion injury had a statistically significant injury dose-dependent reduction of Vt during room air exposure during the first 2 weeks after injury (p ≤ 0.037) (Fig. 2B, Table 1). Additionally, the data revealed a lesion dose-dependent posthemicontusion increase in room air f, resulting in a shallow, rapid breathing pattern during the first 2 weeks after injury (p ≤ 0.044; GLM with post hoc multiple linear regression) (Table 1), which was consistent with our previous reports (Teng et al., 1999, 2003). Room air ventilatory parameters (f, Vt, and Ve) in hemicontused rats recovered to levels not statistically different from controls 2 weeks after injury.

To document respiratory dysfunction of a more chronic nature, rats were also challenged with 7% CO2. Hypercapnic challenge has been demonstrated to elicit respiratory deficits with greater sensitivity than room air experimentally (Teng et al., 1999, 2003; Golder et al., 2001). Moreover, profoundly reduced Vt, f, and Ve responses to hypercapnia have been well documented in chronic tetraplegics in the clinical literature (Manning et al., 1992). We found a significantly diminished ability in hemicontused rats to augment Vt when challenged by 7% CO2 that was injury dose dependent (p = 0.007; GLM with post hoc multiple linear regression), resulting in a severely mitigated Vt response during the first 4 weeks after SCI (p ≤ 0.031; GLM with post hoc multiple linear regression) (Table 1). For instance, there was a 24.8% decrease in hypercapnic Vt in severely injured rats at 2 weeks after SCI and a 13.5% decrease at 4 weeks after SCI compared with uninjured controls. Moreover, there was a clear injury dose-related trend in the loss of the ability to augment f when breathing 7% CO2 (p ≤ 0.063 GLM with post hoc multiple linear regression). Overall, these data indicated that there were injury dose-dependent chronic abnormalities in the post-SCI respiratory parameters in our C5 hemicontusion model.

Respiratory deficits after C5 hemicontusion SCI correlate with lesion pathology

At 4 weeks after SCI, rats with behavioral scores representative of the corresponding group average were selected from each study
Figure 2. More severe grades of C5 hemicontusion injury resulted in greater loss of postinjury body weight and higher degrees of respiratory dysfunction. A, The effect of lesion dose (uninjured control vs 12.5, 25, or 50 mm C5 hemicontusion injury) is shown to correlate inversely with body weight during the 6 week post-SCI course. Note that rats with 50 mm injuries did not recover to control levels, even after 6 weeks (*p < 0.05; Spearman correlation). Ctrl, Control; p.i., postinjury. B, Representative ventilatory parameters at 2 weeks after SCI versus uninjured controls. Error bars represent SEM. *p < 0.05; GLM, post hoc multiple linear regression. mod, Moderate injury. Left, Respiratory frequency as a function of lesion dose (uninjured control vs 12.5, 25, or 50 mm C5 hemicontusion injury) and CO₂ exposure (room air, 5% CO₂, or 7% CO₂). The CO₂ level was a significant covariate across all lesion dose groups (p < 0.001). Lesion dose was a significant covariate during room air ventilation (p = 0.037). Rats with more severe lesions had a tendency for greater resting respiratory frequency while breathing room air but had a diminished augmentation of response to hypercarbic stimulus. Middle, Tidal volume as a function of lesion dose and CO₂ exposure. The CO₂ level was a significant covariate across all lesion dose groups (p < 0.001). Lesion dose was a significant covariate during room air ventilation and 5% and 7% CO₂ ventilation (p = 0.017). Right, Minute ventilation as a function of lesion dose and CO₂ exposure. The CO₂ level was a significant covariate across all lesion dose groups (p < 0.001). Rats with all grades of C5 hemicontusion injury, resulting from a combination of higher f and diminished VT, had resting VE similar to those of controls while breathing room air. When challenged with hypercapnic stimulus, rats with C5 hemicontusion injury displayed a lesion dose-dependent diminished augmentation of minute ventilation response compared with uninjured controls (p = 0.035 at 5% CO₂; p < 0.001 at 7% CO₂).

Table 1. Lesion dose-dependent respiratory parameters after C5 hemicontusion SCI

<table>
<thead>
<tr>
<th>Injury dose</th>
<th>Day 1</th>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 4</th>
<th>Week 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>/ (bpm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>103.0 ± 2.2</td>
<td>172.5 ± 4.9</td>
<td>108.0 ± 3.3</td>
<td>171.6 ± 3.5</td>
<td>105.2 ± 2.8</td>
</tr>
<tr>
<td>12.5 mm</td>
<td>112.8 ± 1.5</td>
<td>166.0 ± 2.0</td>
<td>112.0 ± 2.0</td>
<td>163.2 ± 2.2</td>
<td>108.7 ± 1.8</td>
</tr>
<tr>
<td>25 mm</td>
<td>122.5 ± 1.6</td>
<td>148.7 ± 2.9</td>
<td>116.0 ± 2.2</td>
<td>154.9 ± 2.4</td>
<td>112.7 ± 1.9</td>
</tr>
<tr>
<td>50 mm</td>
<td>132.2 ± 2.4</td>
<td>136.9 ± 4.4</td>
<td>120.0 ± 3.6</td>
<td>146.6 ± 3.9</td>
<td>115.7 ± 3.1</td>
</tr>
<tr>
<td>Ventilation (ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1.35 ± 0.01</td>
<td>2.74 ± 0.05</td>
<td>1.32 ± 0.03</td>
<td>2.75 ± 0.08</td>
<td>1.33 ± 0.03</td>
</tr>
<tr>
<td>12.5 mm</td>
<td>1.24 ± 0.02</td>
<td>2.36 ± 0.04</td>
<td>1.28 ± 0.02</td>
<td>2.58 ± 0.05</td>
<td>1.30 ± 0.02</td>
</tr>
<tr>
<td>25 mm</td>
<td>1.14 ± 0.02</td>
<td>1.98 ± 0.04</td>
<td>1.25 ± 0.02</td>
<td>2.41 ± 0.05</td>
<td>1.25 ± 0.02</td>
</tr>
<tr>
<td>50 mm</td>
<td>1.02 ± 0.03</td>
<td>1.69 ± 0.06</td>
<td>1.18 ± 0.04</td>
<td>2.24 ± 0.09</td>
<td>1.22 ± 0.03</td>
</tr>
<tr>
<td>Adjusted *</td>
<td>0.432 ± 0.784</td>
<td>0.196 ± 0.375</td>
<td>0.150 ± 0.249</td>
<td>0.424</td>
<td>0.092 ± 0.332</td>
</tr>
<tr>
<td>/ (ml/min)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.001</td>
<td>p = 0.007</td>
</tr>
<tr>
<td>12.5 mm</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>25 mm</td>
<td>0.026</td>
<td>0.434</td>
<td>0.026</td>
<td>0.216</td>
<td>0.374</td>
</tr>
<tr>
<td>50 mm</td>
<td>0.035</td>
<td>0.335</td>
<td>0.035</td>
<td>0.235</td>
<td>0.375</td>
</tr>
</tbody>
</table>

Respiratory frequency (bpm, breaths per minute), tidal volume, and minute ventilation measured by WBP in conscious, unrestrained rats with no SCI (n = 19) or after 12.5 (n = 12), 25 (n = 12), or 50 (n = 15) mm C5 hemicontusion injury (× 10 g; Huf IMPactor) at 1 d and 1, 2, 4, and 6 weeks after SCI in room air (0.03% CO₂) and under hypercapnic conditions (5% or 7% CO₂ plus 90% O₂ and N₂ balance). Week 3 data did not differ significantly from week 4 data and are not presented. Four rats from each group were killed after collection of respiratory data at week 4 for histological studies; thus, week 6 data represent 15, 8, and 11 animals for the control, 12.5, 25, and 50 mm groups, respectively. All parameters represent means (corrected by linear regression for group differences in body weight) ± SE of the linear prediction of the mean. The asterisk indicates primary GLM positive (p < 0.05; post hoc linear regression). The dagger symbol indicates nonlinearity (linear regression post hoc).
caudal to the epicenter ($r \approx 0.537; p \approx 0.028$; Spearman correlation), with partial involvement of the C4 and C6 levels in the most severe cases.

To explore whether neuronal loss is responsible for postinjury respiratory abnormalities (Teng et al., 1999), we stained the immediately adjacent transverse sections with cresyl violet ($n = 13$; four uninjured controls and three of each injury severity). We observed an injury dose-dependent loss of ventral motoneurons ($r = 0.768; p \approx 0.006$; Spearman correlation) (Fig. 3B) on the hemicontused side in each section up to 2 mm rostral and 1 mm caudal to the epicenter relative to controls. Note that the numbers of ventral motoneurons at 2 mm rostral to the epicenter ($a1$, $a4$), and 2 mm caudal from the epicenter ($a2$, $a5$) in rats representative of mild injury (top; $a1$–$a3$) and severe injury (bottom; $a4$–$a6$) at 4 weeks after SCI. Scale bar, (in $a1$) 500 μm. $b$, Cresyl violet transverse sections 2 mm rostral to the epicenter in a representative severe hemicontusion injury ($b1$) at 4 weeks after SCI versus an uninjured control ($b2$) rat. Arrowheads indicate ventral motoneurons. $b3$, A representative ventral motoneuron (oil immersion) displaying Nissl substance, a euchromatic nucleus, and a distinct nucleolus. Scale bars: $b1$–$b3$, 20 μm.

**Figure 3.** Histopathological changes after C5 hemicontusion injury. $a$, Solvent blue plus hematoxylin and eosin transverse sections 2 mm rostral from the epicenter ($a1$, $a4$), at the epicenter ($a2$, $a5$), and 2 mm caudal from the epicenter ($a3$, $a6$) in rats representative of mild injury (top; $a1$–$a3$) and severe injury (bottom; $a4$–$a6$) at 4 weeks after SCI. Scale bar, (in $a1$) 500 μm. $b$, Cresyl violet transverse sections 2 mm rostral to the epicenter in a representative severe hemicontusion injury ($b1$) at 4 weeks after SCI versus an uninjured control ($b2$) rat. Arrowheads indicate ventral motoneurons. $b3$, A representative ventral motoneuron (oil immersion) displaying Nissl substance, a euchromatic nucleus, and a distinct nucleolus. Scale bars: $b1$–$b3$, 20 μm.

**Effect of C5 hemicontusion SCI on general somatic neurobehavioral function**

We recorded the neurobehavioral effects of our C5 hemicontusion model using modified Tarlov (Gale et al., 1985) and modified BBB scales (Basso et al., 1995) for the forelimbs and hindlimbs, respectively (Fig. 4). Forelimb and hindlimb neurobehavioral scores contralateral to the hemicontusion injury recovered to preoperative baselines during the first week after SCI. In contrast, ipsilateral locomotor function remained abnormal for all 6 weeks after injury. For the forelimb, there was a significant inverse correlation between injury dose and ipsilateral modified Tarlov scores at all time points from 1 d to 6 weeks after SCI ($r = -0.695; p < 0.001$; Spearman correlation). Injury dose and ipsilateral hindlimb modified BBB scores were also inversely correlated at all time points from 1 d to 6 weeks after injury ($r = -0.735; p < 0.001$; Spearman correlation). Overall, these data demonstrated chronic somatomotor deficits in the ipsilateral forelimbs and hindlimbs, which did not recover to baseline preoperative levels even after 6 weeks after injury. Respiratory function, in contrast, improved to levels comparable with uninjured controls at 2 and 4 weeks after injury, in room air or hypercapnic ventilation, respectively.

**Figure 4.** Forelimb and hindlimb neurobehavioral function declined after C5 hemicontusion injury in lesion dose-dependent manners. Top, Neurobehavioral function of the forelimb (measured by a modified Tarlov scale) on the side ipsilateral to the hemicontused spinal cord correlated inversely with lesion dose (uninjured control vs 12.5, 25, or 50 mm C5 hemicontusion injury) from 1 d to 6 weeks after SCI ($p < 0.05$; Spearman correlation). Bottom, Neurobehavioral function of the hindlimb (measured by a modified BBB scale) on the side ipsilateral to the hemicontused spinal cord correlated inversely with lesion dose (uninjured control vs 12.5, 25, or 50 mm C5 hemicontusion injury) from 1 d to 6 weeks after SCI ($p < 0.05$; Spearman correlation). ctrl, Control; p.i., postinjury.

5-HT1A agonists ameliorate respiratory deficits resulting from C5 hemicontusion SCI

Serotonin is well known to be a key modulator of respiration in the CNS (Zhou and Goshgarian, 2000; Fuller et al., 2005) (for review, see Mitchell and Johnson, 2003). In particular, agonists of the 5-HT1A subreceptor have been shown to improve respiratory
function experimentally (Lalley et al., 1994; Sahibzada et al., 2000; Teng et al., 2003) and clinically (Mendelsohn et al., 1991). Although the precise mechanisms are not clear, antibody studies have demonstrated the presence of 5-HT1A on the axon hillocks of ventral horn motoneurons in the cervical spinal cord of primates (Kheck et al., 1995), possibly indicating a direct stimulatory pathway (Takahashi and Berger, 1990; Richmonds and Hudgel, 1996). Because the greatest density of 5-HT1A receptors is found in the superficial layers of the dorsal horns of the spinal cord (Thor et al., 1993; Kheck et al., 1995), we also reasoned that 5-HT1A agonists may, alternatively, act on a pathway involving the afferents from respiratory muscles to supraspinal respiratory centers (Teng et al., 1999).

To further investigate the putative role of 5-HT1A receptor agonists in post-SCI respiration in C5 hemicontrusion SCI, a subset of rats with mild (n = 9), moderate (n = 9), or severe (n = 12) injuries and 13 controls underwent testing with 8-OH DPAT at 2 and 4 weeks after SCI. Although long-term effects of the 8-OH DPAT treatments in SCI rats were not systematically examined, no significant differences were noted between the pretreatment respiratory parameters of rats that received occasional 5-HT1A treatments and those that did not receive treatment during the 2 or 4 week postinjury course (data not shown). This indicated that 5-HT1A agonists did not produce early tolerance. The present data revealed that 8-OH DPAT (250 µg/kg, i.p.) reversed respiratory abnormalities for all rats with hemicontusion injury at both 2 and 4 weeks after injury (Fig. 5A, Table 2). During room air ventilation at 2 weeks after SCI, we observed that 8-OH DPAT
corrected Vt deficits for all groups with hemicontusion SCI (p = 0.038; repeated-measures ANOVA with post hoc Tukey’s tests) and significantly reduced f in rats in the severely injured group (p = 0.047; repeated-measures ANOVA with post hoc Tukey’s tests), eliminating the shallow, rapid breathing pattern noted before treatment. During 7% CO₂ challenge, 8-OH DPAT treatment significantly improved Vt for all hemiconfused groups at 2 weeks (p = 0.001) and 4 weeks (p = 0.033; repeated-measures ANOVA with post hoc Tukey’s tests) after injury relative to pre-treatment Vt to levels comparable with unlesioned control rats. For instance, severely injured rats at 2 weeks after injury mounted a Ve response to hypercapnic conditions that was ~77% of unjured controls, whereas after the severely injured rats received 8-OH DPAT, their response improved by 37.6% (p < 0.001; repeated-measures ANOVA with post hoc Tukey’s tests) compared with before treatment or ~105% compared with unjured controls. At 2 weeks after SCI, moderately injured rats improved their hypercapnic Ve by 39.2% (p < 0.001) and mildly injured rats by 27.1% (p < 0.001; repeated-measures ANOVA with post hoc Tukey’s tests) compared with predrug baselines to levels comparable with unjured control rats. At 4 weeks after SCI, when predrug baseline hypercapnic Ve for hemiconfused animals were improved but still not normal, 8-OH DPAT improved Ve by 8.4% in mildly injured rats (p = 0.033), 9.2% in moderately injured rats (p = 0.025), and 28.5% in severely injured rats (p = 0.001; repeated-measures ANOVA with post hoc Tukey’s tests). Rats without hemicontusion SCI did not display any statistically significant change in ventilatory parameters after 8-OH DPAT treatment at the equivalence time points. As documented previously (Teng et al., 2003), no significant neurobehavioral changes in any group were noted after 8-OH DPAT administration. No discernible adverse effects to any of the drugs under the current dose regimens were noted (Bjorvatn et al., 1997).

To confirm that 5-HT₁A receptor agonism plays a central role in respiratory function recovery after 8-OH DPAT administration, a dose washout study, a dose–response study, and additional tests using another 5-HT₁A agonist buspirone and 5-HT₁A-specific antagonist p-MPPI were performed with randomly selected subsets of rats receiving severe hemicontusion (Table 3) (Teng et al., 2003). At 5 d after SCI, an 8-OH DPAT dose washout study (250 µg/kg; n = 4) demonstrated a restoration of Vt response to hypercapnia, which peaked during the first hour after injection, lasted up to 4 h, and then subsequently returned to pretreatment levels (p = 0.024; repeated-measures ANOVA with post hoc Tukey’s test) (Fig. 5B). These results were consistent with our previous data that showed a prolonged (i.e., 4 h), but not permanent, amelioration of post-SCI respiratory dysfunction after a single intraperitoneal administration of 8-OH DPAT (Teng et al., 2003). The four rats that received 8-OH DPAT at 5 d after SCI did not display differences in respiratory parameters on subsequent WBP testing for the remainder of their studies compared

### Table 2. Effects of 8-OH DPAT on respiration after SCI

<table>
<thead>
<tr>
<th>Time after SCI</th>
<th>DPAT 12.5 mg</th>
<th>Control</th>
<th>DPAT 25 mg</th>
<th>Control</th>
<th>DPAT 50 mg</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f (bpm)</td>
<td>0.03%</td>
<td>100.4 ± 3.2</td>
<td>111.0 ± 4.2</td>
<td>116.4 ± 3.4</td>
<td>110.8 ± 4.4</td>
<td></td>
</tr>
<tr>
<td>+ 0.03%</td>
<td>101.1 ± 1.9</td>
<td>108.3 ± 2.1</td>
<td>113.4 ± 3.7</td>
<td>107.1 ± 2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.702</td>
<td>p = 0.422</td>
<td>p = 0.638</td>
<td>p = 0.027*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vt (ml)</td>
<td>0.03%</td>
<td>1.34 ± 0.04</td>
<td>1.31 ± 0.03</td>
<td>1.26 ± 0.03</td>
<td>1.22 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>+ 0.03%</td>
<td>1.31 ± 0.03</td>
<td>1.47 ± 0.04</td>
<td>1.46 ± 0.07</td>
<td>1.48 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.203</td>
<td>p = 0.002*</td>
<td>p = 0.016*</td>
<td>p = 0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ve (ml/min)</td>
<td>0.03%</td>
<td>133.7 ± 4.3</td>
<td>144.8 ± 6.2</td>
<td>146.2 ± 3.3</td>
<td>134.8 ± 5.5</td>
<td></td>
</tr>
<tr>
<td>+ 0.03%</td>
<td>131.7 ± 2.8</td>
<td>159.6 ± 5.1</td>
<td>164.9 ± 9.5</td>
<td>149.6 ± 5.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.468</td>
<td>p = 0.069</td>
<td>p = 0.043*</td>
<td>p = 0.099</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f (bpm)</td>
<td>0%</td>
<td>181.1 ± 4.2</td>
<td>163.7 ± 5.5</td>
<td>169.7 ± 3.8</td>
<td>160.7 ± 7.3</td>
<td></td>
</tr>
<tr>
<td>+ 0%</td>
<td>182.0 ± 2.5</td>
<td>188.4 ± 3.8</td>
<td>194.5 ± 6.2</td>
<td>183.7 ± 6.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.155*</td>
<td>p = 0.023*</td>
<td>p = 0.001*</td>
<td>p = 0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vt (ml)</td>
<td>0%</td>
<td>2.91 ± 0.06</td>
<td>2.73 ± 0.08</td>
<td>2.42 ± 0.08</td>
<td>2.49 ± 0.07</td>
<td></td>
</tr>
<tr>
<td>+ 0%</td>
<td>2.86 ± 0.05</td>
<td>3.04 ± 0.10</td>
<td>2.94 ± 0.16</td>
<td>3.03 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.494*</td>
<td>p = 0.001*</td>
<td>p = 0.023</td>
<td>p = 0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ve (ml/min)</td>
<td>0%</td>
<td>527.1 ± 18.3</td>
<td>449.4 ± 27.3</td>
<td>412.0 ± 20.6</td>
<td>403.3 ± 26.4</td>
<td></td>
</tr>
<tr>
<td>+ 0%</td>
<td>535.8 ± 10.4</td>
<td>571.5 ± 13.8</td>
<td>573.6 ± 38.9</td>
<td>555.1 ± 17.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p = 0.494*</td>
<td>p = 0.001*</td>
<td>p = 0.005*</td>
<td>p = 0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3. Effects of various agents with 5-HT₁A receptor activity on respiration after SCI

<table>
<thead>
<tr>
<th>Time after SCI</th>
<th>Control 12.5 mg</th>
<th>Control 25 mg</th>
<th>Control 50 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>f (bpm)</td>
<td>182.9 ± 8.5</td>
<td>294.0 ± 0.9</td>
<td>537.2 ± 29.6</td>
</tr>
<tr>
<td>Vt (ml)</td>
<td>160.7 ± 7.3</td>
<td>250.0 ± 0.01</td>
<td>404.2 ± 26.8</td>
</tr>
<tr>
<td>Ve (ml/min)</td>
<td>173.9 ± 6.3</td>
<td>277.0 ± 0.06</td>
<td>479.7 ± 15.6</td>
</tr>
</tbody>
</table>

### Effects of systemic 8-OH DPAT (250 µg/kg) administration on respiratory parameters (f, Vt, and Ve) for rats without SCI (n = 13) in mL or mg (% change) compared with baseline (f, p = 0.001; repeated-measures ANOVA). Respiratory parameters for injured rats were significantly affected by 8-OH DPAT administration at either 2 or 4 weeks after the baseline period (p < 0.05; repeated-measures ANOVA with post hoc Tukey’s tests).
with the other severely injured rats, suggesting no long-term effect on respiratory function after the single 8-OH DPAT injection at 5 d after SCI (data not shown). Finally, 8-OH DPAT administration did not enhance respiratory response to 7% CO₂ in control rats.

In the dose–response study performed at 2 weeks after SCI (n = 12), a dose-dependent restoration of hypercapnic Ve response was observed. The 250 µg/kg dose of 8-OH DPAT produced the greatest improvement in Ve versus predrug baseline (37.2% increase; p < 0.001), followed by the 125 µg/kg dose (18.6% increase; p < 0.038; repeated-measures ANOVA with post hoc Tukey’s tests) (Fig. 5C, Table 3). In other separate studies during the second week after injury, preadministration of p-MPPI (3 mg/kg, i.p.), given 20 min before 8-OH DPAT, blocked the beneficial effects of 8-OH DPAT (250 µg/kg). Whereas 8-OH DPAT (250 µg/kg) significantly improved hypercapnic Ve compared with the predrug baseline (p < 0.001; see above) when p-MPPI was given before 8-OH DPAT, hypercapnic Ve did not significantly differ from predrug baseline (p > 0.05; repeated-measures ANOVA with post hoc Tukey’s test). Buspirone (1.5 mg/kg, i.p.; n = 12), like 8-OH DPAT, also improved Ve under hypercapnic conditions significantly greater than the predrug baseline (29.8% increase; p = 0.003) to levels indiscernible from the pre-SCI response (p > 0.05; repeated-measures ANOVA with post hoc Tukey’s tests). Together, the results strongly supported the proposition that the respiratory benefits seen in our model were mediated through 5-HT₁₅ receptors.

**Discussion**

Previous reports examining respiratory dysfunction after SCI examined pathophysiology in either thoracic models or anesthetized rats (El-Bohy et al., 1998; Teng et al., 1999, 2003; Golder et al., 2001). These studies were pivotal but showed only transient dysfunction or were necessarily terminal. This is the first report of the impact of a contusive cervical SCI on respiratory function in conscious rats with chronic clinical manifestations. Our model offers feasible laboratory procedures while emulating the epidemiology of disease and the clinical features of post-SCI respiratory dysfunction (Gruner, 1992; Manning et al., 1992). Using this model, we demonstrated that systemic 5-HT₁₅ agonists counteracted post-SCI respiratory abnormalities without discernable adverse effects.

**Greater chronicity of respiratory dysfunction after C5 hemicontrusion than thoracic SCI likely to be associated with phrenic nucleus involvement in the C5 model**

We speculate that involvement of the phrenic nucleus ipsilateral to the hemicontrusion was accountable for the greater chronicity of respiratory deficits in our cervical model than after T8 SCI. The phrenic nucleus of the rat is a longitudinal column of cells located between the ventromedial and ventrolateral cell groups of the ventral horn, extending from C3 to C5 or sometimes C6 (Kuzuhara and Chou, 1980; DeVries and Goshgarian, 1989). Here, we demonstrated an obliteration of this midventral region at the C5 epicenters of all hemicontrused groups, with the loss extending partially through the C4 and C6 levels. Thus, the hemidiaphragm ipsilateral to the hemicontrusion was, at least in part, denervated.

Although the precise contribution of the rat diaphragm to various respiratory parameters has yet to be described, indubitably, the diaphragm plays a more significant role than the lower thoracic intercostals in rodent respiration (e.g., the human diaphragm normally contributes ~65% of vital capacity) (Ledsom and Sharp, 1981). Thus, after midcervical injury, potential natural compensatory mechanisms involving the intercostals are not likely to fully compensate for diminished diaphragmatic function, whereas in the thoracic injury model, increased diaphragmatic function might overcome respiratory deficits attributable to intercostal muscle dysfunction. A more fruitful compensatory measure after C5 hemicontrusion is likely to be increased diaphragmatic drive via supraspinal pathways. Our observation of an increased f during the early postinjury period was compatible with this postulation. However, this rapid breathing pattern can be detrimental to gas exchange and culminate in hypoxemia or frank respiratory failure (Ledsom and Sharp, 1981; Rochester, 1993).

**Eventual recovery of respiratory function**

The eventual recovery of respiratory dysfunction observed in this study is consistent with clinical observations (Bluechardt et al., 1992). Although mechanisms underlying this recovery are essentially unknown, it is well documented that a hemiparetic diaphragm ipsilateral to a C2 hemisectioned cord can regain function shortly after the contralateral phrenic nerve is transected, or spontaneously ~4 weeks after injury (O’Hara and Goshgarian, 1991; Nantwi et al., 1999; Golder et al., 2003). The so-called “crossed phrenic phenomenon” works by reactivating silent synapses of the bulbospinal pathways that cross the spinal midline caudal to the C2 lesion (O’Hara and Goshgarian, 1991). Because our hemicontrusion SCI obliterated the majority of the ipsilateral phrenic area, the recovery was unlikely to be mediated by crossed phrenic pathways.

Alternatively, respiratory recovery may have been partially caused by reinnervation of the hemicontrusion SCI-denerivated hemidiaphragm through axonal sprouting from spared ipsilateral phrenic neurons, contralateral phrenic neurons, and/or phrenic terminals. This reinnervation may potentially have been enhanced by our 5-HT₁₅ agonist administrations, because 5-HT₁₅ activation triggers functional respiratory neural plasticity (Giroux et al., 1999; Mantilla and Sieck, 2003). However, the delay in our initial administration of 5-HT₁₅ agonists fell far beyond the therapeutic windows for tissue preservation after SCI (Teng et al., 1997, 1998, 2004), precluding any hope for 5-HT₁₅ agonist-triggered neuroprotection in our study. Nevertheless, it remains to be examined whether earlier and/or more frequent administration of serotoninergic agonists can further improve or elicit a more prompt neuroplasticity for respiratory recovery.

**Amelioration of respiratory dysfunction by 5-HT₁₅ agonists**

In our study, we observed a temporary restoration (lasting up to 4 h) of respiratory function in C5-injured rats after systemic 5-HT₁₅ agonists at 2 and 4 weeks after injury. The mechanism by which 5-HT₁₅ agonists improve respiration after SCI is not clear (Teng et al., 2003). One possibility is through a dorsal horn afferent–supraspinal respiratory center pathway (Thor et al., 1993; Jankowska et al., 1997; Teng et al., 2003). Briefly, respiratory muscle afferents can influence brainstem respiratory centers and ultimately affect motor output to the skeletal muscles responsible for breathing. It has been suggested that the transfer of information from these respiratory muscle afferents to supraspinal centers may be gated by descending serotoninergic, presumably 5-HT₁₅ pathways (Jankowska et al., 1997; Teng et al., 2003). Buspirone and 8-OH DPAT may act on the dorsal horns of rats with SCI to modulate these pathways and restore normal respiratory function (Teng et al., 2003). We observed a correlation between hypercapnic Ve responses and motoneuronal count in the rostral, but not caudal, margins of the lesion epicenter. It is
our speculation that any positive modulation of the dorsal spinal–supraspinal pathway would trigger a corresponding increase in Ve response to hypercapnia, because the rostral marginal motoneurons would primarily have synaptic continuity with supraspinal centers.

Another possible mechanism explaining the effect of 5-HT₁₆ agonists is via diaphragmatic–thoracic reflex loops. Such reflexes increase accessory respiratory neuronal output (i.e., thoracic motor neurons that control intercostal and abdominal muscles) after their activation by phrenic sensory input from diaphragmatic proprioreceptors and mechanoreceptors (Goshgarian and Roubal, 1986). After hemiconus SCI, certain ipsilateral propriospinal fibers could still be stimulated by contralateral hemidiaphragmatic contraction (Monteau and Hilaire, 1991). Serotonin 1A agonists may have stimulated this reflex loop, a testable hypothesis for future experiments.

It might be postulated that our observed respiratory recovery could have been augmented through 5-HT₂ receptors activation and expression, as reported after C2 hemisection (Zhou et al., 2001; Fuller et al., 2005) and cervical dorsal rhizotomy (CDR) (Kinkead et al., 1998). Post-CDR rats displayed increased serotonin-immunoreactive terminals on phrenic motor neurons, and the consequent long-lasting enhancement of phrenic motor output triggered by hypoxia was blocked by pretreatment with a 5-HT₂-specific antagonist. However, 8-OH DPAT and buspirone used in our work are 5-HT₁₆ specific. 8-OH DPAT, for instance, has an ~1000-fold selectivity for the 5-HT₁₆ over the other 5-HT receptors (Middlemiss and Fozard, 1983), and its respiratory effect observed in this study was completely blocked by p-MPPⅠ, a highly specific 5-HT₁₆ antagonist (Kᵢₛ₈-HT₁₆ = 1.0 μM vs Kᵢₛ₈-HT₂ = 270 nm) (Kung et al., 1994). Nevertheless, we are currently testing whether coadministration of 5-HT₁₆ and 5-HT₂A agonists would synergistically or additively improve post-SCI respiratory recovery.

The evidence supporting a direct supraspinal action for 5-HT₁₆ agonists in post-SCI respiratory dysfunction is less clear. Although 5-HT₁₆ presynaptic and postsynaptic receptors are well known to be distributed in supraspinal areas such as the limbic regions, dorsal raphe nuclei, and various cortical regions and have complex interactions (Blier and Ward, 2003), the respiratory effects after 5-HT₁₆ agonist exposure are unclear. Respiratory frequencies, for instance, have increased in some reports (Mandal et al., 1990; Rose et al., 1995) while remaining level in others (King and Holtman, 1990). Moreover, complexities in the study designs, including dose and route of drug administration (e.g., intravenous, intraventricular, or direct parenchymal injection), anesthesia use, or use of decerebrate models make interpretations of these studies difficult. Anesthesia is a particularly troublesome factor in the study of serotonin and respiration, because anesthetics may easily reduce the excitatory serotonergic input to motoneurons (Rose et al., 1995). In vitro brainstem–spinal cord preparations of neonatal rats have shown that addition of 8-OH DPAT to the superfuse increased respiratory frequency to 28 ± 7% greater than controls (Monteau et al., 1994). Other studies have shown that 8-OH DPAT has little effect on output from key brainstem respiratory centers (Johnson et al., 1996, 2001). However, emphasis must be made that none of these models incorporated a clinically relevant SCI in their designs.

Additional studies will be needed to precisely define the mechanisms through which 5-HT₁₆ agonists ameliorate respiratory dysfunction in this experiment and others. In light of the pressing need for clinical therapeutics applicable to post-SCI respiratory dysfunction and the availability of buspirone, a well tolerated clinical 5-HT₁₆ agonist used as an anxiolytic, we believe that 5-HT₁₆ agonists may offer a novel strategy for treating post SCI respiratory dysfunction. These data, together with the fact that 5-HT₁₆ agonists corrected respiratory deficits in rats with a significant loss of one of their primary phrenic nuclear regions, suggest that strategies aimed at augmenting function and/or expression levels of 5-HT receptors should be further explored to develop treatments for SCI via functional repair of the gray matter (Teng et al., 1999, 2003; Reier et al., 2002) in addition to the well studied tactics for white matter protection (Teng and Wrathall, 1997; Stys, 1998; Waxman, 2002). Importantly, our model will allow additional investigations of other promising pharmaceutical avenues for this highly morbid and occasionally fatal complication of SCI (Nantwi et al., 2003).

References


